6 recruiting, 3 active not recruiting, 1 completed. 10 Phase 1, 5 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 1 | 10 | Recruiting 6, Active not recruiting 3, Completed 1 |
| Phase 2 | 5 | Recruiting 3, Active not recruiting 1, Completed 1 |
Follow SX-682: new trials by email Literature Review of SX-682 trials Research Report on SX-682
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Docetaxel and SX-682 in Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma, Salivary Gland Carcinoma, and Advanced Prostate Cancer SX-682, DTX - Head and Neck Cancer, Head and Neck Squamous Cell Carcinoma | Phase 1 / Phase 2 | Recruiting | National Cancer Institute (NCI) | 120 | 2026-11-02 | 2026-10-28 |
| A Study of SX-682 in Combination With Proton Craniospinal Irradiation (pCSI) in People With Leptomeningeal Disease SX-682, Proton Craniospinal Irradiation (pCSI) - Leptomeningeal Disease (LMD) | Phase 1 | Recruiting | Memorial Sloan Kettering Cancer Center | 40 | 2026-09-04 | 2026-09-11 |
| Investigating SX-682 in Combination With Apalutamide in Metastatic Castration-resistant Prostate Cancer SX-682, Apalutamide - Metastatic Castrate-Resistant Prostate Cancer (mCRPC) | Phase 1 / Phase 2 | Recruiting | Institute of Cancer Research, United Kingdom | 78 | 2025-04-28 | 2026-09-08 |
| SX-682 in Combination With Carfilzomib, Daratumumab-Hyaluronidase, and Dexamethasone in Patients With Relapsed or Refractory Multiple Myeloma Cxcr1/2 Inhibitor SX-682, Daratumumab and Recombinant Human Hyaluronidase, Carfilzomib - Recurrent Multiple Myeloma, Refractory Multiple Myeloma | Phase 1 | Recruiting | Roswell Park Cancer Institute | 15 | 2025-04-10 | 2026-08-13 |
| Phase I/II Study of the Combination Immunotherapy Regimen: SX-682, TriAdeno Vaccine, Retifanlimab and IL-15 Agonist N-803 (STAR15) for Metastatic Colorectal Cancer (mCRC) Retifanlimab, Therapeutic CEA, Brachyury and MUC1 TriAdeno Vaccine Platform, N-803 - Metastatic Colorectal Cancer | Phase 1 / Phase 2 | Recruiting | National Cancer Institute (NCI) | 60 | 2024-03-26 | 2026-10-16 |
| Phase I/II Trial Investigating the Safety, Tolerability, Pharmacokinetics, Immune and Clinical Activity of SX-682 in Combination With BinTrafusp Alfa (M7824 or TGF-beta "Trap"/PD-L1) With CV301 TRICOM in Advanced Solid Tumors (STAT) SX-682, M7824, MVA-BN-CV301 - Metastatic Cancer, Solid Tumors | Phase 1 / Phase 2 | Completed | National Cancer Institute (NCI) | 12 | 2020-11-24 | 2025-02-03 |
| A Study to Evaluate the Safety and Tolerability of SX-682 in Combination With Nivolumab as a Maintenance Therapy in Patients With Metastatic Pancreatic Ductal Adenocarcinoma SX-682, Nivolumab Injectable Product - Pancreatic Ductal Adenocarcinoma, Pancreatic Cancer | Phase 1 | Active not recruiting | University of Rochester | 20 | 2020-11-23 | 2026-07-06 |
| SX-682 and Nivolumab for the Treatment of RAS-Mutated, MSS Unresectable or Metastatic Colorectal Cancer, the STOPTRAFFIC-1 Trial CXCR1/2 Inhibitor SX-682, Nivolumab - Metastatic Colon Adenocarcinoma, Metastatic Colorectal Carcinoma | Phase 1 / Phase 2 | Active not recruiting | M.D. Anderson Cancer Center | 51 | 2020-10-14 | 2026-07-20 |
| Study of SX-682 Alone and in Combination With Oral or Intravenous Decitabine in Subjects With Myelodysplastic Syndrome SX-682, Decitabine - Myelodysplastic Syndromes | Phase 1 | Recruiting | Syntrix Biosystems, Inc. | 151 | 2020-06-30 | 2025-12-23 |
| SX-682 Treatment in Subjects With Metastatic Melanoma Concurrently Treated With Pembrolizumab SX-682, Pembrolizumab - Melanoma Stage III, Melanoma Stage IV | Phase 1 | Active not recruiting | Syntrix Biosystems, Inc. | 77 | 2019-06-12 | 2025-12-23 |
Colorectal Neoplasms (2) · Prostatic Neoplasms (2) · Carcinoma (1) · Carcinoma, Adenoid Cystic (1) · Colonic Neoplasms (1) · Head and Neck Neoplasms (1) · Hypopharyngeal Neoplasms (1) · Laryngeal Neoplasms (1) · Melanoma (1) · Meningeal Neoplasms (1) · Multiple Myeloma (1) · Myelodysplastic Syndromes (1) · Nasopharyngeal Carcinoma (1) · Neoplasm Metastasis (1) · Pancreatic Neoplasms (1)
National Cancer Institute (NCI) (3) · Syntrix Biosystems, Inc. (2) · Institute of Cancer Research, United Kingdom (1) · M.D. Anderson Cancer Center (1) · Memorial Sloan Kettering Cancer Center (1) · Roswell Park Cancer Institute (1) · University of Rochester (1)
United States (9) · Switzerland (1) · United Kingdom (1)
Alisha Bent, MD (1) · Charalampos Floudas, M.D. (1) · Daniel Mulkerin, MD (1) · David A Sallman, MD (1) · James L Gulley, M.D. (1) · Jens Hillengass, MD (1) · Monica Chen, MD (1) · Nicholas P Tschernia, M.D. (1) · Professor Johann de Bono, MB ChB, FRCP, MSc, PhD, FMedSc (1) · Stuart Kahn, M.D. (1)
R44CA217591 (1), R44CA291622 (1), R44HL142389 (1)